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Animal welfare has become a recent issue in the policy of the European
Union. Since the creation of the European Economic Community (EEC) in
1957, the welfare of animals was only considered in relation to the proper
functioning of the common market. Animals were seen as commodities
whose interests were intertwined with agricultural and environmental pol-
icy. Over the years, the position has changed somewhat. Although a treaty
basis exists for animal welfare, the protection of animals has not yet been
recognized as an important policy area of its own, and thus worthy of legal
protection. As a positive step in recognizing the unnecessary suffering of ani-
mals, the Cosmetics Directive will be the focus in the first part of this article.
The amendments to the Cosmetics Directive to prohibit the testing of ani-
mals in cosmetics culminated in the case of France v. European Parliament
and the Council of the European Union. The European Court of Justice and
the Advocate General held against France and upheld the seventh amend-
ment of the Cosmetics Directive. Similar measures were adopted in Califor-
nia, which will be discussed in the second half the article. Chapter 476, now
a California statute, has banned animal testing except where there are no
validated alternatives available. Chapter 476 is not without its critics, ow-
ing to its omission of standing for animal welfare groups. This has been the
subject of both academic and judicial debate, and the analysis suggests that
it will prove difficult for such groups to establish standing. Nevertheless,
California is the first state to introduce legislation that prohibits the testing
of cosmetics on animals, and this has prompted others to follow suit, with
New York in the process of introducing similar legislation.
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I. INTRODUCTION
While animal welfare has made great strides since the seven-
teenth century, speaking of legal rights for animals has aroused much
debate and consternation. This can be attributed to the fact that not all
human beings have equal legal rights.1 For many years, animals were
denied rights because humans believed that animals’ apparent lack of
communication skills meant animals also lacked reason.2 It was
thought that animals acted only on instinct owing to their inferior
mental and emotional intellect to humans.3 As a result, “animals were
thought to be simply machines, with their bodies interpreting environ-
mental stimuli and translating them into behavior.”4 Since they lacked
reason, Descartes argued that animals were not conscious of the exper-
iences that surrounded them and, as a result, were incapable of suffer-
1 Tom Regan, The Case for Animal Rights 267 (U. Cal. Press 2004); see also Christo-
pher  D. Stone, Should Trees Have Standing?—Toward Legal Rights for Natural Ob-
jects, 45 S. Cal. L. Rev. 450, 450–51 (1972) (discussing how originally legal rights were
granted to a narrow sector of society and, in some cases, were confined to those within a
kinship).
2 Rene´ Descartes formulated this idea in the seventeenth century. See Paola
Cavalieri, The Animal Debate: A Re-examination, in In Defense of Animals: The Second
Wave 58 (Peter Singer ed., Blackwell Publg. 2006).
3 Susan E. Davis & Margo Demello, Stories Rabbits Tell: A Natural and Cultural
History of a Misunderstood Creature 334 (Lantern Bks. 2003).
4 Id. (adding that “[h]umans, on the other hand, were granted a vast array of
learned behaviors, individual emotions and particular personalities that are shaped by
a myriad of factors—including culture, the local environment, historical conditions, so-
cioeconomic positions and, with the discovery of the modern science of genetics, inher-
ited traits.”).
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ing.5 Animals were viewed as inanimate objects, pieces of personal
property that could not be ascribed rights.6
Moral rights, on the other hand, are more amenable to animals,
with some people arguing that humans have duties towards animals.7
In this situation, humans have an indirect duty towards animals, as
the duty only arises in situations where it is in the interest of the
human being.8
As Kant argued, “he who is cruel to animals becomes hard also in
his dealings with men.”9 Notwithstanding the philosophical debate, re-
cent developments in both the European Union (EU)10 and the United
States (U.S.) suggest that animals are sentient beings and deserve the
paternalistic protection of the law. This paper will begin with a discus-
sion of Directive 76/768/EEC (Cosmetics Directive)11 in the EU and
will then discuss similar developments under California law and the
5 Cavalieri, supra n. 2, at 58.
6 Lauren Magnotti, Student Author, Pawing Open the Courthouse Door: Why Ani-
mals’ Interests Should Matter When Courts Grant Standing, 80 St. John’s L. Rev. 455,
465 (2006).
7 Cass R. Sunstein, Standing for Animals, 47 UCLA L. Rev. 1333, 1336 (2000); id.
at 1336 n. 15.
8 Id. at 1136 n. 15 (citing the opinion of Immanuel Kant).
9 Immanuel Kant, Lectures on Ethics 240 (Louis Infield trans., Harper & Row 1978)
(originally published in 1930).
10 The EU currently has twenty-seven Member States; originally there were six:
France, Germany, Italy, Belgium, Luxembourg, and the Netherlands. Jo Steiner, Lorna
Woods & Christian Twigg-Flesner, EC Law 93–94 (8th ed., Oxford U. Press 2006).
These States signed the European Coal and Steel Community (ECSC) Treaty in 1952.
Id. In 1957, the six original Member States signed two more Community Treaties, the
European Economic Community (EEC) Treaty and the European Atomic Energy Com-
munity. Id. The EEC was more economic in nature than the ECSC and had as its aim
the creation of a common market between the six founding States. Id. The next impor-
tant development was the Single European Act 1986. Id. at 5. Although called an Act,
this Treaty intended to create an internal market, remove custom duties, and create a
common customs tariff. The Treaty on European Union 1992 (also known as the Maas-
tricht Treaty) created the three pillar structure. Europa, European Treaties, http://
europa.eu/abc/treaties/index_en.htm (accessed Apr. 7, 2007). The three pillars are the
Community Pillar, the Common Foreign and Security Policy Pillar, and Justice and
Home Affairs Pillar. In 1997, the Treaty of Amsterdam was introduced and made
changes to the Pillars. Id. In 2001, the Treaty of Nice was signed and this Treaty intro-
duced changes into the Commission. Id. It extended qualified majority voting, broad-
ened the functions of the Court of First Instance, and created a new body—Eurojust—to
coordinate activities in the fight against transnational crime. More recently, the EU has
consolidated all the earlier Treaties into one Treaty, the Constitutional Treaty, which
has yet to be adopted by all the Member States. Id.
11 Council Directive 76/768, 1976 O.J. (L 262) 169 (EEC) [hereinafter Cosmetics
Directive] (available at http://eur-lex.europa.eu/LexUriServ/site/en/consleg/1976/L/
01976L0768-20060809-en.pdf) (on file with Animal L.). A directive is a secondary piece
of legislation that is binding on the Member States, but it is up to each Member State
how it wishes to incorporate the directive into the national legal system. See Treaty
Establishing the European Community, art. 249, Dec. 29, 2006, O.J. (C321E) 153 [here-
inafter EC Treaty]; Steiner, Woods & Christian Twigg-Flesner, supra n. 10, at 3. The
Official Journal (OJ) states when the directive is to be enacted, with a time frame of up
to four years. If a Member State does not incorporate the directive within the proscribed
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contentious issue of legal standing. The paper will conclude with a dis-
cussion of future developments.
II. THE EUROPEAN UNION AND ANIMAL WELFARE
Animal welfare in the EU was recently called an “issue of very
high importance.”12 The European Commission (Commission)13 recog-
nizes animals as sentient beings and has a general aim of the avoid-
ance of pain and suffering of animals.14 The Commission obliges the
owners or keepers of animals to respect minimal animal welfare re-
quirements.15 However, animals are still not recognized as having le-
gal rights.
In the past, animal welfare received inadequate attention in the
EU, and those protections that did exist were concerned with the
proper functioning of the internal market.16 The Treaty on European
Union referred to animal welfare in the form of a Declaration.17 The
Treaty of Amsterdam (TA) then included a protocol on animal wel-
fare.18 An important feature of this protocol was the reference to ani-
time, individuals may still be able to invoke the directive against their Member State in
their national court under the principle of direct effect. See generally id. at 88–105.
12 Markos Kyprianou, Speech, Speech to the Animal Welfare Intergroup of the Euro-
pean Parliament (Brussels, June 8, 2005) (available at http://ec.europa.eu/food/animal/
welfare/speech_05_335_en.pdf).
13 EC Treaty art. 7 provides for institutions that are entrusted with carrying out the
tasks of the Community, one of which is the Commission. The Commission embodies
and upholds the general interest of the Union; it is often referred to as the “Guardian of
the Treaties.” It formulates recommendations and opinions on matters dealt with in the
Treaty, participates in the shaping of measures taken by the Council, and exercises
powers conferred on it by the Council. See EC Treaty, supra n. 11, at  arts. 211–19
(detailing the Commission and its duties).
14 Eur. Commn., Animal Welfare—Introduction, http://europa.eu.int/comm/food/
animal/welfare/index_en.htm (accessed Feb. 9, 2007).
15 Id.
16 For examples, see EC Treaty, supra n. 11, at art. 37 (governing agriculture); EC
Treaty art. 95 (governing the internal market); EC Treaty, supra n. 11, at art. 175 (gov-
erning environmental issues).
17 Treaty on European Union, Declaration on the Protection of Animals, July 29,
1992, 1992 O.J. (C 191) (available at http://eur-lex.europa.eu/en/treaties/dat/11992M/
htm/11992M.html#0103000044); see Tara Camm & David Bowles, Animal Welfare and
the Treaty of Rome—A Legal Analysis of the Protocol on Animal Welfare and Welfare
Standards in the European Union, 12 J. Envtl. L. 197, 198 (2000) (stating that while
the Declaration called for the European Parliament, the Council and the Commission,
and the Member States to regard animal welfare, it had little legal effect).
18 See Treaty of Amsterdam amending the Treaty on the European Union, Protocol
on Protection and Welfare of Animals, Oct. 11, 1997, 1997 O.J. (C 340) 110 [hereinafter
TA Protocol] (stating that “[i]n formulating and implementing the Community’s agricul-
tural, transport, internal market and research policies, the Community and the Mem-
ber States shall pay full regard to the welfare requirements of animals, while respecting
the legislative or administrative provisions and customs of the Member States relating
in particular to religious rites, cultural traditions and regional heritage”) (available at
http://www.europarl.europa.eu/topics/treaty/pdf/amst-en.pdf). The Treaty of Amster-
dam introduced “for the first time legal obligations enshrined within the EC Treaty to
have regard to animal welfare in key areas of European law and policy.” Camm &
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mals as “sentient beings.”19 However, the TA did not provide any legal
basis for the introduction of legislation in relation to animal welfare.20
The protection of animals has been intertwined with other policy is-
sues such as agriculture or the environment.21 Consequently, animal
welfare has yet to be recognized as an important policy area of its own,
and thus worthy of legal protection. The Treaty Establishing a Consti-
tution for Europe attempts to give animal welfare a more tangible le-
gal basis.22 Article III-121 is very similar to the protocol in that it
recognizes animals as sentient beings, but its effect is weakened by the
exception given to Member States on the basis of religious rites and
cultural traditions.23
III. THE EUROPEAN UNION AND ANIMAL TESTING
In 1976, the European Community (EC) introduced the Cosmetics
Directive to approximate the laws of the Member States in relation to
cosmetic products.24 The Cosmetics Directive aims to determine “at
Community level the regulations which must be observed as regards
the composition, labeling and packaging of cosmetic products . . . .”25
The EC introduced the Cosmetics Directive after much deliberation be-
tween experts from all the Member States.26
The aim was two-fold: to guarantee the safety of cosmetic products
for human use and thus benefit the consumer, and to encourage com-
mercial exchange between the Member States, thus eliminating barri-
ers to trade.27 At the time of the Cosmetics Directive, no provisions
existed relating to animal welfare.
Bowles, supra n. 17, at 197. “The protocol also leaves Member States free to introduce
national legislation relating to issues such as animal welfare in circuses, equine compe-
titions, greyhound racing, hunting with hounds, and bullfighting.” Eurogroup for Ani-
mals, The Treaty and Animal Welfare, http://eurogroupforanimals.org/legislation/
legislation_more1.htm?#art1 (accessed Feb. 10, 2007).
19 TA Protocol, supra n. 18. “Sentient beings” refers to animals being viewed as ani-
mate and living creatures as opposed to goods.
20 Id.
21 See EC Treaty, supra n. 1.
22 Treaty Establishing a Constitution for Europe, Part III: The Policies and Func-
tioning of the Union, Title I Provisions of General Application, art. III-121, Oct. 29,
2004, 2004 O.J. (C 310) 55, 55–56 [hereinafter Constitutional Treaty] (available at
http://eurlex.europa.eu/LexUriServ/site/en/oj/2004/c_310/c_31020041216en00550185
.pdf).
23 Id. at 56.
24 Cosmetics Directive, 1976 O.J. (L 262) at 169.
25 Id. Britain, Austria, and the Netherlands have already prohibited animal test-
ing in cosmetics. Humane Socy. U.S., French Government Challenges EU Cosmetics
Directive, http://www.hsus.org/animals_in_research/animals_in_research_news/
french_government_challenges_eu_cosmetics_directive.html (accessed Apr. 7, 2007).
26 Commn. Eur. Communities, The Rules Governing Cosmetics Products in the Euro-
pean Union, Volume 1: Cosmetics Legislation—Cosmetic Products iii (Off. for Official
Publications of the European Communities 1999) (available at http://leffingwell.com/
cosmetics/vol_1en.pdf).
27 Cosmetics Directive, 1976 O.J. (L 262) at 169.
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In 1993, Directive 93/35/EEC incorporated a new Article 4(1)(i)
into the Cosmetics Directive which provided that Member States, in
order to comply with the requirements of the Directive, were obliged to
prohibit the marketing of cosmetic products containing ingredients
that had been tested on animals.28 The January 1, 1998 deadline was
postponed to June 30, 2000—and then to June 30, 2002—as an insuffi-
cient number of alternative testing methods had been scientifically
validated.29
In April 2000, the Commission proposed a seventh amendment to
the Cosmetics Directive.30 The Commission proposed, inter alia, to in-
troduce a testing ban on animals for finished cosmetic goods within the
Member States.31 It also proposed that the marketing ban—a prohibi-
tion on the sale and marketing of cosmetic products that have been
tested on animals—contained in the Cosmetics Directive be
removed.32
In February 2002, the Council33 adopted a Common Position on
the proposed amendment and reinstated the marketing ban on cos-
metic products where the final product or its ingredients have been
subject to animal testing.34 However, the Council made the implemen-
tation of the marketing ban subject to the existence of alternative test-
ing methods accepted within the framework of the Organization for
Economic Co-Operation and Development (OECD) toxicity test guide-
28 Council Directive 93/35, 1993 O.J. (L 151) 32, 33 (EEC).
29 Commn. Directive 97/18, art. 1, 1997 O.J. (L 114) 43, 44 (EC) (postponing the 1998
deadline to June 30, 2000); Commn. Directive 2000/41, art. 1, 2000 O.J. (L 145) 25, 25
(EC) (the second postponement to June 30, 2002).
30 Commn. Eur. Communities, Proposal for a Directive of the European Parliament
and of the Council Amending for the Seventh Time Council Directive 76/768/EEC on
the Approximation of the Laws of the Member States Relating to Cosmetic Products, at 2,
COM (2000) 189 final (Apr. 5, 2000) [hereinafter Commn. Eur. Communities, COM
(2000) 189] (on file with Animal L.).
31 Id. Article 1(3)(a) defines a “finished cosmetic product” as the cosmetic product in
its final formulation, as placed on the market and made available for sale to the final
consumer, or its prototype. Council Directive 2003/15, Amending Council Directive 76/
768/EEC, 2003 O.J. (L66) 26 (EC) [hereinafter CDA, which stands for Cosmetics Direc-
tive Amendment] (available at http://ec.europa.eu/enterprise/cosmetics/doc/200315/
200315_en.pdf) (on file with Animal L.). “Prototype” is defined as a first model or design
that has not been produced in batches, and from which the finished cosmetic product is
copied or finally developed. Id. at art. 1(3)(b), 2003 O.J. (L66) at 29.
32 Commn. Eur. Communities, COM (2000) 189 at 2.
33 The Council consists of one representative from each Member State. Unlike the
Commission, the Council does not have fixed membership. The “basic” Council consists
of the Foreign Ministers of the Member States, who discuss not only foreign affairs, but
also issues of general concern. However, if a more specialized area is under discussion,
the Council will consist of ministers from that policy area, for example the ministers for
Agriculture and Trade. The members must be “at ministerial level, [authorized] to com-
mit the government of that Member State.” See generally EC Treaty, supra n. 11, at art.
203.
34 Council Common Position (EC) No. 29/2002 of 14 February 2002, art. 1, 2002 O.J.
(C 113) 109, 110 (on file with Animal L.).
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lines and those adopted at the EC level.35 The Common Position did
not include deadlines for the implementation of the marketing ban.
In June 2002, the Parliament36 adopted a position on the Coun-
cil’s Common Position.37 It suggested a number of amendments, in-
cluding the introduction of a marketing ban when alternative methods
of testing became available.38 The Parliament also suggested a defini-
tive date after which no cosmetic products could be marketed if tested
on animals, irrespective of there being validated alternatives at that
time.39 In July 2002, the Commission adopted an Opinion on the Par-
liament’s amendments to the Council’s Common Position.40 In its
Opinion, the Commission rejected the Parliament’s proposal to reintro-
duce the marketing ban.41 A conciliation committee of the Parliament
and the Council was convened in October and November 2002.42 The
Council and the Parliament consequently approved the joint text.43
This text represents a compromise between the respective positions of
the Parliament and the Council. In 2003, the Parliament introduced
an amendment to the Cosmetics Directive.44
Amending Council Directive 2003/15/EC (CDA) amends the Cos-
metics Directive to add Article 4a, which prohibits the sale of any new
or existing product that has been tested on animals in disregard of
35 Id.
36 In 1957, under the EEC (which was changed to the European Community Treaty
(EC) under the Treaty on European Union in 1993), the Parliament was termed an
Assembly with a supervisory and advisory role. The early treaties provided this “Assem-
bly” with very few powers. Over the years, the role of the Assembly changed, and in
1986, under the Single European Act, its name was changed to the Parliament. The
Parliament is not a legislature in the commonly accepted sense of that term, as it has no
power of initiation (legislation) and no right to raise taxes. However, in recent years, it
has played an increasingly powerful role in the decision making process. See EC Treaty
arts. 189–201.
37 Eur. Parl. Comm. on the Env., Pub. Health & Consumer Policy, Recommendation
for a Second Reading on the Council Common Position for Adopting a European Parlia-
ment and Council Directive Amending Council Directive 76/768/EEC, Doc. (A5-0180)
(2002) (available at http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//
NONSGML+REPORT+A5-2002-0180+0+DOC+PDF+V0//EN&language=EN).
38 Id. at 6–7.
39 Id. at 7.
40 Commn. Eur. Communities, Opinion of the Commission on the European Parlia-
ment’s Amendments to the Council’s Common Position, COM (2002) 435 final (July 26,
2002) [hereinafter Commn. Eur. Communities, COM (2002) 435] (on file with Animal
L.).
41 Id. at 4.
42 Eur. Parl. Conciliation Comm., Report on the Joint Text Approved by the Concilia-
tion Committee for a European Parliament and Council Directive of the European Par-
liament and of the Council Amending Council Directive 76/768/EEC, Doc. (A5-0001) ¶
5, 6 (2003) [hereinafter Eur. Parl. Conciliation Comm., Conciliation Report, Doc. (A5-
0001)] (available at http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//
NONSGML+REPORT+A5-2003-0001+0+DOC+PDF+V0//EN&language=EN) (on file
with Animal L.).
43 Id. at 4.
44 CDA, 2003 O.J. (L66) at 26.
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existing alternative testing methods.45 Article 4a(1) prohibits the
following:
(a) the marketing of cosmetic products where the final formulation, in or-
der to meet the requirements of this Directive, has been the subject of
animal testing using a method other than an alternative method after such
alternative method has been validated and adopted at Community level
with due regard to the development of validation within the OECD;
(b) the marketing of cosmetic products containing ingredients or combina-
tions of ingredients which, in order to meet the requirements of this Direc-
tive, have been the subject of animal testing using a method other than an
alternative method after such alternative method has been validated and
adopted at Community level with due regard to the development of valida-
tion within the OECD;46
(c) the performance on their territory of animal testing of finished cosmetic
products in order to meet the requirements of this Directive;
(d) the performance on their territory of animal testing of ingredients or
combinations of ingredients in order to meet the requirements of this Di-
rective, no later than the date on which such tests are required to be re-
placed by one or more validated alternative methods.47
Article 4a(1) will come into force in 2009; thus Member States
have until then to implement it.48 This will result in a near total ban
on the marketing and testing of animals for cosmetic products.49
Under Article 4a(2), the Commission was given the task of establishing
timetables for the implementation of the provisions under Articles
4a(1)(a), (b), and (d).50 Article 4a(1)(c), concerning the prohibition of
animal testing for finished cosmetics, had to be implemented by Sep-
tember 11, 2004,51 while Articles 4a(1)(a), (b), and (d) are to be imple-
mented by March 2009.52 This marketing ban was to be incorporated
into national legislation by Member States by September 2004. Imple-
45 Id. at 28.
46 Id. (Article 4a(2) establishes that the maximum time limit for this, and specifi-
cally for tests of repeated-dose toxicity, reproductive toxicity, and toxicokinetics where
there are no alternatives under consideration, is ten years.).
47 Id.
48 Id. at 28.
49 Id. at 28–29.
50 CDA, 2003 O.J. (L 66) at 28. These timetables were to be established following
consultation with various groups, including the Scientific Committee on Cosmetic Prod-
ucts and Non-Food Products intended for Consumers (SCCNFD) and the European Cen-
tre for the Validation of Alternative Methods (ECVAM). Id. Due regard was also to be
had for the Organisation for Economic Cooperation and Development (OECD) guide-
lines in relation to the development of validation. Id. “ECVAM was created by a Com-
munication from the Commission to the Council and the Parliament in October, 1991”
in response to a requirement in Directive 86/609/EEC. See ECVAM, About ECVAM:
Reason for EVCAM, http://ecvam.jrc.it/index.htm (accessed Feb. 13, 2007) (explaining
that Directive 86/609/EEC requires the Commission and the Member States to actively
support the development, validation, and acceptance of methods which could reduce,
refine, or replace the use of laboratory animals).
51 CDA, 2003 O.J. (L66) at 28.
52 Id.
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mentation was postponed,53 because the Commission and the Council,
while advocating a ban on animal testing if validated alternatives ex-
ist, objected to a marketing ban on cosmetic goods.54 Cosmetic product
tests regarding repeated dose toxicity, reproductive toxicity, and tox-
icokinetics, where there are not yet validated alternatives, must be
banned by 2013.55 However, this deadline is extendable if non-animal
alternatives are still unavailable by 2013.56
France objected to the CDA and issued annulment proceedings
against the Council and the Parliament in French Republic v. Euro-
pean Parliament and Council of the European Union.57 In May 2005,
the European Court of Justice (ECJ) handed down judgment in the
case and dismissed the action.58
The main source of contention for France was Article 1(2) of the
CDA, which introduces a new Article 4a into the original Cosmetics
Directive.59 Article 4a(1) will prohibit the testing of cosmetics on ani-
mals and the marketing of such products in the EU.60 The near total
ban is to come into force by March 2009, but if no valid alternatives
exist by 2009, a total prohibition must be implemented by 2013.61
France objected to the contested provision, arguing that it infringed
upon the principles of legal certainty, proportionality, precaution, non-
discrimination, and the freedom to pursue a professional activity.62 On
53 Humane Socy. U.S., French Government Challenges EU Cosmetics Directive,
http://www.hsus.org/animals_in_research/animals_in_research_news/
french_government_challenges_eu_cosmetics_directive.html) (Jan. 24, 2005).
54 Id.
55 CDA, 2003 O.J. (L66) at 28.
56 Id. at art. 1(2.2) at 28–29.
57 Case C-244/03, French Republic v. European Parliament and the Council of the
European Union, 2003 O.J. (C 171) 20. EC Treaty art. 230 provides that Member
States, the Council, the Commission, and the Parliament may request annulment of a
Community provision. Annulment proceedings also give the Court of Justice the oppor-
tunity to examine the legality of acts adopted by the Community institutions. Council
Directive 325/33, art. 230, 2002 O.J. (C 325) 126 (EC). Under EC Treaty art. 231, if the
proceedings are found to be justified, the disputed act may be declared null and void. Id.
at 127. France was the only Member State to publicly object to the ban on animal test-
ing and marketing of animal tested cosmetics products. Humane Socy. U.S., supra n.
53.
58 Case C-244/03, Judgment of the Court in French Republic v. European Parliament
and Council of the European Union, 2005 E.C.R. I-04021 [hereinafter Case C-244/03,
Judgment, 2005 E.C.R. I-04021] (on file with Animal L.).
59 CDA, 2003 O.J. (L66) at 28.
60 Id.
61 Id.
62 Case C-244/03, Judgment, 2005 E.C.R. I-04021 at ¶ 7; see also Azalea P. Rosholt,
The Seventh Amendment Directive—An Unnecessary Measure to a Necessary End—Pos-
sible Legal Challenges to Directive 2003/15/EC of the European Parliament and of the
Council Amending Council Directive 76/768/EEC under European Union Law, 60 Food
& Drug L.J. 421, 431–33 (2005) (making a number of interesting arguments that Article
4a is legally deficient).
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May 24, 2005, the Grand Chamber of the ECJ held that the partial
annulment sought was impossible, and the action was dismissed.63
IV. FRANCE V. THE COMMISSION AND PARLIAMENT
France argued that Article 1(2) of the CDA, which introduces Arti-
cle 4a into the Cosmetics Directive, should be annulled and severed
from the other provisions of the CDA, which would continue to have
legal effect.64 The French government believed that Article 1(2) of the
CDA infringed the principle of legal certainty.65 France’s argument
centered on the EC legislature’s failure to define clearly and precisely
the scope of Article 4a, as well as the use of the expression “in order to
meet the requirements of this Directive,” which the French Govern-
ment felt would result in the CDA being transposed in divergent ways
in the national legal systems of the Member States.66
France also raised the argument that legal certainty is even more
important when it places obligations on individuals.67 Due to the im-
precise nature of Article 4a, France argued that the lack of clarity
would render cosmetics companies incapable of determining what cir-
cumstances and legal relationships fell within the scope of that arti-
cle.68 Given that cosmetic companies need to maintain their position
on the international markets and avoid falling behind in developing
innovative products, France contended that the cosmetic industry in
Europe should be able to determine exactly what is intended by the
CDA.69 The French government alluded to its position as EU leader in
the cosmetic sector, with half of its turnover being earned from expor-
tation.70 France submitted that legal certainty was necessary to main-
tain the competitive position of the EU cosmetic industry, as the
number of substances usable in the cosmetics industry would be
greatly diminished if the contested provision were not severed from
the rest of the Directive.71
63 Case C-244/03, Judgment, 2005 E.C.R. I-04021.
64 Id. at ¶ 1.
65 Id. at ¶ 7.
66 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 ¶ 32 (2005) (on file with Animal L.).
67 Id.
68 Id.
69 Id. at ¶ 33.
70 Id. at ¶ 33. France is home to L’Oreal, Clarence, and Clinique. L’Oreal owns,
among others, the following brands: Garnier, Maybelline NY, Kerastase, Lancoˆme, Bi-
otherm, Helena Rubenstein, Kielh’s, Georgio Armani, Ralph Lauren, shu uemura,
Cacheral, Viktor & Rolf, Vichy, La Roche-Posay, and inne´ov. China, Korea, Japan, and
to some extent the United States, are main importers of EU cosmetics, and these coun-
tries require that cosmetics are safe for human use before market authorization will be
granted.
71 Id. at ¶ 33.
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A. Partial Annulment
The French government also proposed a partial annulment of Ar-
ticle 4a insofar as it infringed on the freedom to pursue a professional
activity.72 France reasoned that such interference was excessive, intol-
erable, and contrary to the principle of proportionality.73 France also
argued that the intended aim of the CDA, improving animal welfare,
was extremely small; while the implementation of Article 4a would, in
France’s view, present a significant risk to human health due to a
dearth of alternative methods of testing.74 France claimed that the
principle of precaution had been infringed, as the legislature had al-
lowed human health to be exposed to unacceptable risks.75 Finally,
France argued that the contested Article infringed on the principle of
non-discrimination because it has the potential to upset the level of
equality among companies in the cosmetic industry and gave no objec-
tive reason.76 For example, France contended that companies active
purely in the cosmetics sector could be treated differently from compa-
nies active in other industries, as the latter could use ingredients
tested on animals for other purposes.77
France looked to Article 4a(2.4), which allows a Member State to
request the Commission to grant an exception from Article 4a(1) in
“exceptional circumstances where serious concerns arise as regards
the safety of an existing cosmetic ingredient . . . .”78 The Commission,
after consultation with the Scientific Committee on Cosmetic Products
and Non-Food Products Intended for Consumers (SCCNFP), may
grant an exception in the form of a reasoned decision.79 France argued
that the exception was so strict as to render it ineffective.80
72 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 34.
73 Id.
74 Id. at ¶¶ 35, 37 (estimating that only 0.3% of animal tests are carried out for
cosmetic products); see also Simon Pitman, France Loses Appeal against Testing ban,
http://www.cosmeticsdesign.com/news/news-ng.asp?n=60242-france-loses-appeal (May
25, 2005) (noting eleven million animal experiments in the EU per annum, with cosmet-
ics testing accounting for 0.25%); compare Naturewatch, Compassionate Shopping,
http://www.naturewatch.org/shoppingguide/loreal_response.asp (accessed Feb. 14,
2007) (L’Oreal contends that there are no alternatives for toxicity and skin irritation
tests) with The Interagency Coordinating Comm. on the Validation of Alt. Methods
(ICCVAM) & The Natl. Toxicology Program Interagency Ctr. for the Evaluation of Alt.
Toxicology Methods (NICEATM), infra n. 151 (discussing alternative toxicity and skin
irritation tests).
75 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 37.
76 Id. at ¶ 38.
77 Id.
78 Id. at ¶ 17.
79 Id. The Commission authorizes an exception under the terms of procedure re-
ferred to in CDA, art. 10(2), 2003 O.J. (L 66) at 26–35.
80 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 36.
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B. GATT/WTO Considerations
France argued that the EU provisions on animal testing and the
marketing ban were incompatible with World Trade Organization
(WTO) law on the freedom to pursue a profession.81 France contended
that the protection of animals did not constitute an EC objective of
general interest that warranted a restriction of this freedom.82 As
WTO rules prohibit the discrimination against foreign products,83
France argued that the marketing ban would breach this provision.84
In the words of Advocate General (AG) Geelhoed, France argued that
the marketing ban amounted “to an economic embargo to force other
members to adopt essentially the same global regulations in order to
achieve an objective defined on Community territory.”85
Article XX of the General Agreement on Tariffs and Trade (GATT)
allows an exception to free trade.86 France acknowledged the aim of
Article XX (the protection of the life and health of animals), but con-
tended that less onerous measures would have obtained the same ob-
jective without breaching WTO rules.87 However, in 2000, Article XX
was used in the U.S. to ban the importation and sale of dog and cat fur
products.88 In light of this decision, France’s argument in relation to
Article XX was weakened.
C. The Opinion of the Advocate General Geelhoed
Advocate General Geelhoed delivered his Opinion on March 17,
2005.89 The AG looked at the legislative background of the Cosmetics
81 See id. at ¶ 34 (describing France’s arguments regarding freedom to pursue a pro-
fession); id. at ¶ 43 (stating “[o]n the basis of these arguments, the French Government
concludes [the Article 4a marketing ban] is incompatible with WTO law”).
82 Id. at ¶ 34.
83 General Agreement on Tariffs and Trade, art. III, § 4 (Oct. 30, 1947), 61 Stat. A-11
[hereinafter GATT] (“The products of the territory of any contracting party imported
into the territory of any other contracting party shall be accorded treatment no less
[favorable] than that accorded to like products of national origin in respect of all laws,
regulations and requirements affecting their internal sale, offering for sale, purchase,
transportation, distribution or use.”) (available at http://www.wto.org/English/docs_e/
legal_e/gatt47_01_e.htm).
84 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 41.
85 Id. at ¶ 42.
86 GATT, art. XX (“Subject to the requirement that such measures are not applied in
a manner which would constitute a means of arbitrary or unjustifiable discrimination
between countries where the same conditions prevail, or a disguised restriction on inter-
national trade, nothing in this Agreement shall be construed to prevent the adoption or
enforcement by any contracting party of measures . . . necessary to protect human,
animal or plant life or health.”).
87 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 42.
88 19 U.S.C. § 1308 (2000). The issue of dog and cat fur being used in clothing im-
ported from Third Countries is discussed in the Speech by Markos Kyprianou. Kypria-
nou, supra n. 12.
89 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021. There are two courts in the Commu-
nity court system: the European Court of Justice (ECJ) and the Court of First Instance
(CFI). The ECJ has eight Advocate Generals (AG). Each AG gives a lengthy opinion on
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Directive,90 the contested Article 4a provision,91 the arguments raised
by the French government,92 and the arguments of the Council93 and
the Parliament.94 The AG looked at the issue of partial annulment of
Article 1(2) of the CDA.95 In his examination of the case law, the AG
found that the contested provision was not severable from the rest of
the CDA, and thus declared the action inadmissible.96 The AG went on
to examine the substance of the parties’ arguments on the hypothesis
that the ECJ might find the contested provision severable.97
On the issue of legal certainty, the AG rejected the arguments
made by France.98 He reasoned that the prohibition on animal testing
applied equally to tests carried out for the purposes of complying with
other legislation, in that substances that had been the subject of such
tests could not be used in cosmetic products.99 Such an interpretation
“seem[ed] necessary for the effet utile of the Directive and is consistent
with the intention expressed in the preparatory documents leading up
to its adoption.”100 From the AG’s interpretation, the contested provi-
sion applied to the carrying out of animal testing of cosmetic products
or ingredients on a Member State’s territory, irrespective of whether
the products were intended for export.101 The AG drew on the wording
of Article 1(7) of the CDA to support this conclusion.102 In the AG’s
opinion, the contested provision did not lack legal certainty, and in the
event of an undertaking questioning its interpretation, a case could be
brought before the national court, which could in turn refer the matter
to the ECJ under Article 234 of the EC Treaty.103 By rejecting the pro-
portionality argument, the AG found that the contested provision “re-
present[ed] a careful and considered balance by the Community
legislature between the interests at stake.”104 In his discussion on the
principle of precaution, the AG referred to Arnold Andre´ GmbH & Co.
all aspects of the case. The opinion will usually conclude with a recommendation. The
AG does not decide the case, nor is his/her reasoning binding on the court, but it carries
significant weight. See generally EC Treaty, supra n. 11, at arts. 220–45.
90 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶¶ 2–10.
91 Id. at ¶¶ 11–19.
92 Id. at ¶¶ 29–43.
93 Id. at ¶¶ 44–51.
94 Id. at ¶¶ 52–58.
95 Id. at ¶¶ 59–70.
96 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶¶ 70, 87, 105, 109–10, 113,
124–25.
97 Id. at ¶ 70.
98 Id. at ¶ 83.
99 Id. at ¶ 84.
100 Id. at ¶ 84.
101 Id. at ¶ 85.
102 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 84.
103 Id. at ¶ 87. EC Treaty Article 234 is a preliminary reference procedure. EC
Treaty, supra n. 11, at art. 234.
104 Id. at ¶ 105.
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KG v. Landrat des Kreises Herford,105 where the ECJ defined the
principle:
When it is impossible to determine with certainty the existence or scope of
an alleged risk due to the insufficient, inconclusive, or imprecise nature of
results or studies, but the probability of real damage to public health per-
sists in the case that the risk would materialize, the principle of precaution
justifies the adoption of the restrictive manner.106
When dismissing France’s argument, the AG made the point that
in order to invoke the principle of precaution, a party must prove that
the alleged risk is more than hypothetical.107 Since the French govern-
ment had not adduced any evidence of “any more than a hypothetical”
risk to public health, its argument on this basis was dismissed.108 Be-
cause the AG had already found that the contested provision did not
lack legal certainty, the French government’s arguments on non-dis-
crimination were also rejected, as these arguments were based on the
hypothesis that Article 1(2) lacked legal certainty.109
On the issue of whether Article 4a restricts the pursuit of a profes-
sional activity, the AG reiterated the comments made by the ECJ in
the case of Metronome Musik GmbH v. Musik Point Hokamp GmbH.110
In that case, the ECJ recognized the right to pursue a professional ac-
tivity, but added that it was not absolute and could be restricted, pro-
vided that the restriction was not disproportionate to the aim it sought
to achieve.111 In using the same analogy, the AG found that the re-
striction did not represent a disproportionate interference with the
freedom to pursue a profession.112 In addressing the relevance of WTO
law, the AG recognized two situations in which the ECJ may review
measures of the EC institutions against the WTO Agreement and its
annexes: “namely, where the Community intended to implement a par-
ticular obligation assumed in the context of the WTO, or where the
Community measure refers expressly to the precise provisions of the
WTO agreements.”113 Because neither of these situations existed, the
AG determined that Article 4a cannot be reviewed in light of the WTO
Agreement and its annexes.114
105 Case C-434/02, Arnold Andre` GmbH & Co. KG v. Landrat des Kreises Herford,
2004 E.C.R. I-11825.
106 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 106 (citing Case C-434/02, 2004
E.C.R. I-11825).
107 Id. at ¶ 107.
108 Id. at ¶ 109.
109 Id. at ¶ 110.
110 Case C-200/96, Metronome Musik GmbH v. Music Point Hokamp GmbH, 1998
E.C.R. I-01953 (on file with Animal L.).
111 Id. at ¶ 21.
112 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 113.
113 Id. at ¶ 115.
114 Id.
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The AG then turned to the arguments raised by France in regard
to Article III.4 of GATT.115 France argued that Article 4a amounted to
a “marketing prohibition of all animal tested cosmetic products that
use a method other than an alternative method after such alternative
method has been validated and adopted at Community level.”116 In
France’s view, such a provision constituted less favorable treatment
within the meaning of Article III.4 of GATT,117 as importers into the
EC are required to “have their alternative method validated at Com-
munity level.”118 The AG rejected this argument and contended that:
While it is clear that this requirement is not discriminatory in law, being
indistinctly applicable to Community and third country manufacturers, it
is equally not wholly evident to me that the effect of such a requirement
would in practice impose a greater competitive burden on third country
manufacturers than on EU companies.119
The AG found that the requirement of EU level validation of alter-
native methods was “justifiable under Article XX(b) GATT,” in that
this requirement satisfied the criterion of necessity120 “within the
meaning of this provision.”121 In his view, the AG could not see an-
other measure being reasonably available to the EU that would qualify
as more consistent with GATT and within the meaning of GATT case
law.122 France had argued that alternative methods should be vali-
dated at the OECD level instead of the EC level, and thus qualify as
more consistent with GATT.123 The AG rejected this argument and
made the valid point that the legislature was aware of this possibility
but had justifiably rejected it.124 He referred to the Commission Propo-
sal of 2000,125 where the Commission emphasized the need for alterna-
tives to be endorsed at the EC level given the moral importance of
welfare within the EC and the number of years it takes for an existing
method to be accepted by all OECD members.126 Thus, the Commis-
sion agreed that regulatory acceptance at the EC level would be more
time efficient.127
115 Id. at ¶ 117; GATT, supra n. 83.
116 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 117.
117 GATT, supra n. 83.
118 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 117.
119 Id. at ¶ 120.
120 See World Trade Org. App. Body Rpt., European Communities-Measures Affecting
Asbestos and Asbestos-Containing Products, pt. VII, art. B, WT/DS135/AB/R (Mar. 12,
2001) (adopted Apr. 5, 2001) (available at http://www.wto.org/English/tratop_e/dispu_e/
135abr_e.pdf) (giving an example of the necessity test).
121 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 121.
122 See id. at ¶ 121 (citing World Trade Org. App. Body Rpt., Korea—Measures Affect-
ing Imports of Fresh, Chilled and Frozen Beef, WT/DS161/AB/R (Jan. 10, 2001)) (availa-
ble at http://docsonline.wto.org/DDFDocuments/t/WT/DS/169ABR.doc).
123 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 117.
124 Id. at ¶ 122.
125 Commn. Eur. Communities, COM (2000) 189 final (Apr. 5, 2000).
126 2005 Op. Adv. Gen. E.C.R. I-04021 at ¶ 122.
127 Id. at ¶ 122.
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In distinguishing the present case from that of United States—
Import Prohibition of Certain Shrimp and Shrimp Products,128 the AG
found that the requirement of EU level validation was “adopted in
good faith, constituted in the Community legislature’s view the only
means of effectively achieving the Directive’s goal of animal protection,
and had the explicit aim of [maximizing] acceptance of EU-approved
alternative methods at OECD level.”129 In dismissing the French gov-
ernment’s case on the above arguments, the AG proposed that the ECJ
should dismiss the action.130
D. The Decision of the European Court of Justice
The ECJ delivered its decision on May 24, 2005.131 In dismissing
France’s annulment action, the ECJ upheld the legality of the seventh
amendment to the Cosmetics Directive.132 The ECJ looked at settled
case law and concluded that partial annulment of an EC Act is only
possible if the part for which annulment is sought can be severed from
the remainder of the Act.133 The ECJ concluded that when partial an-
nulment of the EC Act would result in an alteration of the substance of
the Act, the requirement of severability is not satisfied.134 When ap-
plying an objective criterion135 to decide whether partial annulment
would result in a substantive alteration of the contested Act, the ECJ
found that when the annulment of the contested provision “would ob-
jectively alter the very substance of the provisions adopted by the
Community legislature,” the contested provision could not be sev-
ered.136 Since Article 4a “constitute[s] one of the principal axes of [the
CDA],” severing it would “objectively alter the very substance” of that
128 World Trade Org. App. Body Rpt., United States—Import Prohibition of Certain
Shrimp and Shrimp Product, WT/DS58/AB/R (Oct. 12 1998). The French government
argued that this case was relevant because the Appellate Body found a requirement
that other countries adopt a specific regulatory system that was essentially the same as
the Member’s own. 2005 Op. Atty. Gen. Geelhoed E.C.R. I-04021 at ¶ 123. The Appel-
late Body did this without inquiring to see if such a system was appropriate in light of
the conditions of those countries. Id.
129 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 123.
130 Id. at ¶ 125.
131 Case C-244/03, Judgment, 2005 E.C.R. I-04021.
132 Id.
133 Id. at ¶ 12 (citing Case C-29/99, Commn. European Communities v. Council of the
European Union, 2002 E.C.R. I-11221 at ¶¶ 45, 46; Case C-378/00, Commn. European
Communities v. European Parliament, 2003 E.C.R. I-00937 at ¶¶ 28, 29; Case C-239/01,
Fed. Republic Germany v. Commn. European Communities, 2003 E.C.R. I-10333 at ¶
33).
134 Case C-244/03, Judgment, 2005 E.C.R. I-04021 at ¶ 13 (citing Joined Cases C-68/
94 and C-30/95, French Republic v. Commn. European Communities, 1998 E.C.R. I-
1375, at ¶ 257; Case C-29/99, 2002 E.C.R. I-11221 at ¶ 46; Case C-239/01, 2003 E.C.R. I-
10333 at ¶ 34).
135 See Case C-239/01, 2003 E.C.R. 1-10333 at ¶ 37 (for an example of the court using
an objective criterion).
136 See Case C-244/03, Judgment, 2005 E.C.R. I-04021 at ¶ 15 (concluding that an-
nulment would “alter the very substance” of the provisions relating to animal testing).
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provision, and the court rejected France’s argument.137 The ECJ re-
ferred to Recital 18 of the preamble of the CDA, which provides that
the provisions of the Directive 95/35/EC—banning the marketing of
cosmetic products containing ingredients or combinations of ingredi-
ents tested on animals—should be superseded by the provisions of the
CDA.138 The ECJ found that Article 1(2) was intended to “supersede”
Article 4(1)(i) of the Cosmetics Directive; thus the insertion of Article
1(2) in the Cosmetics Directive and the deletion of Article 4(1)(i) consti-
tuted a non-severable whole.139 Consequently, the partial annulment
of Article 1(2) was not possible and France’s action was therefore dis-
missed as inadmissible.140
V. THE FUTURE OF ANIMAL TESTING IN COSMETICS
IN THE EUROPEAN UNION
By 2009, manufacturers of cosmetic products will no longer be
able to test their products on animals in situations where there is a
validated alternative to animal testing. Products that were previously
tested on animals will continue to be sold. The ban is not retroactive,
as it applies only to ingredients and finished products marketed after
the 2009 and 2013 cutoff dates. Member States have until 2009 to in-
corporate the Cosmetics Directive into their respective national legal
systems. The method of incorporation is up to each Member State,141
but once enacted, the Cosmetics Directive is binding in its entirety.
Member States may adopt the Cosmetics Directive sooner than
2009,142 but if a Member State fails to incorporate it by the deadline, it
may be subject to fines by the ECJ under the principle of state liabil-
ity.143 Until 2009, there will be a near total ban on the testing of prod-
ucts on animals.144 For those products that do not have a validated
alternative to testing on animals by 2009, a four year extension will be
137 Id.
138 Id. at ¶ 17.
139 Id. at ¶ 16.
140 Id. at ¶ 20.
141 CDA, 2003 O.J. (L66) at 28. For instance, in Ireland, the Cosmetics Directive can
be incorporated by way of Statutory Instrument (SI) or Act. European Communities
(Cosmetic Products) (Amendment No. 5), Regulations 2003, SI No. 553/2003 (Ireland’s
version of the Cosmetics Directive). Where it alters existing law, an Act is used; other-
wise, a SI is used. A SI is brought in by the relevant government minister. This is a
more time effective method than introducing a bill.
142 CDA, 2003 O.J. (L66) at 28; see European Communities (Cosmetic Products)
(Amendment No 5), Regulations 2003, SI No. 553/2003. Although animal testing has
been prohibited in the United Kingdom since 1997, the Cosmetics Directive was imple-
mented through the Cosmetics (Safety) Regulations 2004 No. 2152.
143 See Joined Cases C-46/93 and C-48/93, Brasserie du Peˆcheur SA v. Ger. & Queen
v. Sec. State Transp. ex parte Factortame Ltd., 1996 E.C.R. I-01029 at ¶¶ 1, 3, 4, 36
(discussing state liability) (available at http://eur-lex.europa.eu/Notice.do?val=212074);
Steiner, Woods & Twigg-Flesner, supra n. 11 at 111–23 (discussing the principle of
state liability).
144 CDA, 2003 O.J. (L66) at 28.
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allowed.145 This deadline may be extended if non-animal alternatives
are still unavailable by 2013.146
Interestingly, leading cosmetics company L’Oreal contends that
there is no alternative for toxicity and skin irritation tests.147 Until
alternative testing is introduced, animal tests will be used to test for
toxicity and skin irritation.148 However, in the U.S., the Interagency
Coordinating Committee on the Validation of Alternative Methods
(ICCVAM) has validated alternative tests, the two most important be-
ing the Corrisitex149 and the Murine Local Lymph Node Assay
(LLNA),150 which determine skin corrosivity and irritation, respec-
tively.151 In 2001, the European Centre for the Validation of Alterna-
tive Methods (ECVAM) completed validation studies resulting in
approval by the Commission of three in vitro skin corrosivity test
methods and an in vitro phototoxicity assay.152
It is important to note that Article 4a of the CDA does not prevent
companies from developing new products. Accordingly, the EU has a
list of over eight thousand cosmetic ingredients that do not require
animal testing.153 Therefore, there is no reason why cosmetic compa-




147 Naturewatch, Compassionate Shopping, http://www.naturewatch.org/shopping-
guide/loreal_response.asp (accessed Apr. 7, 2007).
148 Id.
149 Megan Erin Gallagher, Toxicity Testing Requirements, Methods and Proposed Al-
ternatives, 26 Environs Envtl. L. & Policy J. 253, 268–69 (2003).
150 Natl. Inst. Health, A Big Step in Reducing Animal Testing: FDA, OSHA and
CPSC Accept Alternative Test for Allergic Contact Dermatitis Following Review, Ap-
proval by an Independent Scientific Panel, http://www.niehs.nih.gov/oc/news/anitest
(accessed Apr. 7, 2007). This test has reduced the number of animals used and virtually
eliminates pain and distress. Gallagher, supra n. 149, at 268. This test was reviewed in
September 1998 and was validated by ICCVAM in February 1999. Id. The Environmen-
tal Protection Agency (EPA), the U.S. Food and Drug Administration (FDA), and the
Occupational Safety and Health Administration (OSHA) announced their acceptance of
the LLNA in October 1999. Id. at 268.
151 ICCVAM & NICEATM, Overview, http://iccvam.niehs.nih.gov/about/overview.htm
(accessed Feb. 14, 2007) (on file with Animal L.).
152 Id.
153 See Ltr. from Brit. Union for the Abolition of Vivisection to the Priv. Sec. to Patri-
cia Hewitt, Sec. State, Dept. Trade Indust., Cosmetics Directive (Nov. 19, 2001) (availa-
ble at http://www.publications.parliament.uk/pa/cm200102/cmselect/cmeuleg/152-xvi/
15205.htm) (“[T]he Commission accepts that there are already more than 8,000 ingredi-
ents safely used in cosmetics without the need for any further animal testing.”) (on file
with Animal L.); Eur. Parl. Comm. on the Env., Pub. Health & Consumer Policy, Reso-
lution on the Commission Report on the Development, Validation, and Legal Acceptance
of Alternative Methods to Animal Experiments in the Field of Cosmetics, at ¶ 4(a),
COM(97) 0182 C4-0369/97 (Oct. 23, 1997) (stating the Cosmetic industry has 8,000 in-
gredients available to use until validated alternatives are available) (on file with
Animal L.).
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VI. DIRECTIVE 2003/15/EC: EFFECTIVENESS AND PROBLEMS
The phased introduction of a prohibition on animal testing is a
positive move on the part of the EU institutions. The ban is two-fold: it
prohibits both the testing of cosmetics on animals and the sale of prod-
ucts (individual ingredients and finished products) that have been
tested on animals.154 However, the CDA is not without its shortcom-
ings, which threaten to denigrate its effectiveness.
The prohibition also applies to products that are imported from
outside the EU.155 This will prove to be troublesome for countries such
as the U.S., where the Food and Drug Administration (FDA) requires
rigorous testing of certain chemicals before they may be used in cos-
metics.156 It is also possible that a rival company could have a competi-
tor’s product tested on animals and thus have it removed from the
market.157 Some believe that the elimination of animal testing will re-
sult in the sale of products that may be injurious to the consumer.158
Arguably, enforcement in relation to third countries will be difficult,
and the number of animals that will benefit from the ban is negligible.
Independent research estimates that of the 11.6 million animals uti-
lized for experimental or scientific purposes in the EU, only 0.3% are
used for cosmetic testing.159 These tests are carried out on rats, mice,
guinea pigs, rabbits, and fish; cosmetic testing is not conducted on
dogs, cats, or primates.160
The institutions, namely the Council, the Commission, and the
Parliament, took different approaches to the wording of the CDA, and
in the end, a compromise had to be reached.161 Both the Commission
and the Council argued that the stipulated time periods for a ban on
animal testing were overzealous given that suitable alternatives had
to be in force by then.162 The Commission felt that the date of the pro-
hibition “should be postponed . . . if there has been insufficient pro-
gress in developing satisfactory methods to replace animal testing
scientifically validated as offering an equivalent level of protection for
154 CDA, 2003 O.J. (L66) at 28.




159 Commn. European Communities, Fourth Report from the Commission to the
Council and the European Parliament on the Statistics on the Number of Animals used
for Experimental and Other Scientific Purposes in the Member States of the European
Union, at 9, COM (2005) 7 final (Jan. 20, 2005) (on file with Animal L.).
160 The European Cosmetic Toiletry & Perfumery Association, Animal Testing: Can
We Do Without? http://www.colipa.com/site/index.cfm?SID=15588&OBJ=15756 (ac-
cessed Feb. 13, 2007).
161 Eur. Parl. Conciliation Comm., Conciliation Report, Doc. (A5-0001).
162 See Commn. Eur. Communities, COM (2002) 435 at 4 (the Commission states that
the time scale for bans is unrealistic); Council Common Position (EC) No. 29/2002 of
14 February 2002, 2002 O.J. (C 113) at ¶10, 115 (the Council favors a stepwise approach
to banning testing because “it is impossible to predict when all necessary alternative
methods . . . could be available.”).
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the consumer.”163 This argument was consistent with the views of the
Economic and Social Committee and the SCCNFP. The SCCNFP ar-
gued “that total abolishment of animal tests within 10 years is not fea-
sible from an objective scientific point of view.”164 The SCCNFP also
called for a clear definition, as well as the consistent and correct use of
the term in vitro throughout the seventh amendment to the Cosmetics
Directive.165 In vitro does not necessarily negate the use of animal
testing, as many cell cultures and tissue cultures are derived from ani-
mals; thus, there is no total replacement of animals in such testing.166
The SCCNFP concluded that the deadlines for abolition of animal
testing were both “too optimistic and not realistic.”167 The Parliament,
the only institution directly elected by the people of the EU, was seem-
ingly motivated by more political concerns.168 The Experimental Ani-
mals Protection Directive,169 enacted prior to the CDA, was introduced
to harmonize the laws in the Member States in relation to animal test-
ing across all industries.170 To some, the seventh amendment is super-
fluous, and its failure to refer to the three Rs—Reduction, Refinement,
and Replacement—has been criticized.171 However, the CDA does call
for:
the systematic use of alternative methods, which reduce the animals used
or reduce the suffering caused, in those cases where full replacement alter-
natives are not yet available . . . when these methods offer consumers a
level of protection equivalent to that of conventional methods which they
are intended to replace.172
While the Cosmetics Directive encourages scientific developments
to incorporate refinement and reduction, until validated alternatives
are introduced, the replacement of animals in cosmetic testing will re-
main but an aspiration.
VII. THE UNITED STATES AND ANIMAL COSMETIC TESTING
The U.S. has taken similar action at a state level to ban the test-
ing of cosmetics on animals. The infamous Draize Eye Irritancy Test
163 Commn. Eur. Communities, COM (2000) 189 at 6.
164 SCCNFP, Opinion Concerning a “Report for Establishing the Timetable for Phas-
ing Out Animal Testing for the Purpose of the Cosmetics Directive” Issued by ECVAM
(30/04/2004), at 2, SCCNFP/0834/04 (adopted July 1, 2004) (available at http://
ec.europa.eu/health/ph_risk/committees/sccp/documents/out285_en.pdf ).
165 Id. at 2.
166 Id.
167 Id. at 18.
168 See Rosholt, supra n. 62, at 426 (“Parliament maintained that public opinion de-
manded the bans regardless of the availability of alternatives.”).
169 Council Directive 86/609, 1986 O.J. (L 358) 1 (EEC) [hereinafter Experimental
Animals Protection Directive] (available at http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=CELEX: 31986L0609 :EN:HTML).
170 Id.
171 Rosholt, supra n. 62, at 424.
172 CDA, 2003 O.J. (L 66) at 26.
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(Draize test) has been long admonished for its barbaric treatment of
rabbits.173 This test was first developed by John H. Draize, Ph.D., Di-
rector of the Dermal and Ocular Toxicity Branch of the FDA.174
Draize and his co-workers developed a technique whereby a
beauty or household product is applied to a rabbit’s eye, skin, or penis
over a twenty-four, forty-eight, or seventy-two hour period.175 In some
cases, the observations last from seven to twenty-one days.176 Rabbits
are placed in a holding device which only exposes their heads so that
they cannot claw out their eyes or escape.177 The subject is usually an
albino New Zealand white rabbit.178 The test is carried out to see
whether signs of blindness, hemorrhaging, bleeding, swelling, ulcera-
tion, and/or discharge occur. Draize was influenced and prompted to
develop his infamous test by an article in the Journal of the American
Medical Association that discussed the “injurious consumer cli-
mate”179 and reported that insufficient eye testing could result in a
number of injuries, ranging from blindness to death.180
In most cases, the rabbit is not anaesthetized during the process,
and is killed after the test has ended.181 Such tests are difficult to jus-
tify, considering that most of these cosmetic products have already
been tested and this duplication is both superfluous and cruel.182 In-
terestingly, because rabbits have a different cornea structure183 and
produce a smaller amount of tears than humans, a substance placed in
the eye of a rabbit will stay there longer and consequently, the irri-
tancy test may produce different results in comparison to humans.184
Not only are animals biologically different from humans, but animals
of the same species may also have biological differences. This has “led
173 Sara Amundson, Changing Laws to Change Toxicology, 2002 AV Mag. 15 (Sum-
mer 2002) (available at http://www.aavs.org/images/AV_Text.qxd.1.pdf); see also Del-
cianna J. Winders, Student Author, Combining Reflexive Law and False Advertising
Law to Standardize “Cruelty Free” Labeling of Cosmetics, 81 N.Y.U. L. Rev. 454 (2006)
(suggesting strategies to diminish false cruelty-free advertising); Stacy E. Gillespie,
Student Author, A Cover-Girl Face Does Not Have to Begin with Animal Cruelty: Chap-
ter 476 Gives Legal Force to Alternative Testing Methods, 32 McGeorge L. Rev. 461
(2001) (considering California Chapter 476’s effect on animal testing for cosmetics).
174 Crystal Miller, The Dreaded Draize Eye Test: Harming the Eye of the Beholder,
2002 AV Mag. 10 (Summer 2002) (available at http://www.aavs.org/images/
AV_Text.qxd.1.pdf).
175 Id. at 10.
176 Id.; Gallagher, supra n. 149, at 258.




181 Miller, supra n. 174, at 10.
182 See Gillespie, supra n.173, at 464 (noting that these duplicated tests are being
carried out for data proposes only).
183 G. Langley & C. Langley, Cosmetics Testing on Animals in France, Cosmetics
Testing on Animals—A Scientific Critique, http://www.experimentation-animale.org/
english/gbcosm_chap4.html (accessed Apr. 7, 2007).
184 Id.
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to the premature approval of chemicals and products which later prove
to be harmful and fatal to humans.”185
The use of the Draize test has long been questioned in the U.S., as
neither the FDA nor federal law requires that the finished cosmetic
products be tested prior to their marketing or sale.186 However, the
“FDA strongly urges cosmetic manufacturers to conduct whatever toxi-
cological or other tests are appropriate to substantiate the safety of
their cosmetics.”187 Some companies use the testing information for
data purposes in the event of a consumer reporting an adverse reaction
to a product.188
A. Senator Jack O’Connell and S.B. 2082
There have been four attempts to criminalize the Draize test in
the state of California.189 The final Senate Bill, S.B. 2082, was signed
by Governor Gray Davis on September 16, 2000.190 S.B. 2082 has been
hailed as a small but significant step, as it is the first statute in the
U.S. to curtail animal testing in the cosmetic industry.191 S.B. 2082
requires manufacturers and their contract testing facilities to stop us-
ing animals in cosmetics testing when alternative validated testing
methods are available.192 It provides for a maximum civil penalty of
$5000 and injunctive relief for breach of the bill.193 It also allows suc-
cessful parties to recover costs and attorneys’ fees.194 S.B. 2082 does
not apply to tests carried out in the interest of medical and pharmaco-
185 See Gallagher, supra n. 149, at 260 (referring to the findings of the U.S. General
Accounting Office, which found that fifty-two percent of all new drugs over a ten year
period had serious toxic and fatal effects that were not discovered in tests carried out on
animals).
186 Miller, supra n. 174, at 11.
187 U.S. Food & Drug Administration Ctr. Food Safety & Applied Nutrition, Cosmetic
Handbook: Regulatory Requirements for Marketing Cosmetics in the United States,
http://www.cfsan.fda.gov/~dms/cos-hdb1.html (1992) [hereinafter FDA].
188 Miller, supra n. 174, at 11.
189 Gillespie, supra n. 173, at 462 n. 10 (Cal. Assembly 2461 (1989) (criminalizing the
Draize test); Cal. Assembly 110 (1991) (narrowing criminal repercussions for use of the
Draize test); Cal. Sen. 777 (1999) (dropped by Senator O’Connell in favor of Cal. Sen.
2082, Reg. Sess. (Feb. 25, 2000)); Cal. Sen. Jud. Comm., Animal Testing: Alternative
Methods SB 2082, Reg. Sess. 2 (Apr. 23, 2000) (available at http://www.leginfo.ca.gov/
pub/99-00/bill/sb_2082_cfa_20000426_103549_sen_comm.html).
190 The Bill added § 1834.8 to the California Civil Code, relating to animal testing.
Cal. Civ. Code §1834.8 was renumbered to Cal. Civ. Code §1834.9 in 2001. Cal. Civ.
Code Ann. § 1834.9(9) (West 2007).
191 Gillespie, supra n. 173, at 474.
192 Cal. Civ. Code Ann. § 1834.9(a) (West Supp. 2007) (validating alternatives would
be those that are accepted by the ICCVAM and adopted by the responsible federal regu-
latory agenc(ies)).
193 Id. at § 1834.9(b).
194 Id. at § 1834.9(d). Those who can bring suit for injunctive relief include the Attor-
ney General, the district attorney of the county in which the violation is alleged to have
been occurred, or a city attorney of a city or a city and county with a population of over
750,000. Id.
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logical research and development.195 In addition, it does not prohibit
the use of animal tests to comply with the requirements of state
agencies.196
S.B. 2082 came in the wake of three failed attempts by Senator
Jack O’Connell to prohibit animal testing. In 1989 and 1990, O’Connell
introduced two bills that attempted to criminalize the use of the Draize
test and the skin irritancy test.197 Both bills were adopted by the legis-
lature but were vetoed by then-Governor Pete Wilson, who argued that
no validated alternative to animal testing existed and that consumer
safety was of paramount importance.198 The second bill, Assembly Bill
(A.B.) 110, was similar to the first bill, but narrowed its scope to pro-
hibit the use of the Draize and skin irritancy tests for household clean-
ing products and cosmetics.199 A.B. 110 reduced the criminal sanction
proposed in A.B. 2461 (the first bill) to a misdemeanor and a fine not
exceeding $2000.200 Again, then-Governor Wilson vetoed the bill, argu-
ing that there was no feasible validated alternative to animal testing
in the foreseeable future.201 In 1999, Senator O’Connell authored a
third bill, S.B. 777, but this was subsequently shelved in favor of S.B.
2082.202 S.B. 777 had almost reached a compromise, but the deadline
lapsed, and O’Connell re-introduced the bill as S.B. 2082 and resumed
negotiations.203
An instigating factor in the creation of S.B. 2082 was enactment at
the federal level of the National Institutes of Health Revitalization Act
of 1993 (NIHRA).204 The NIHRA recognized the fact that the majority
of testing is carried out by regulatory agencies, and in doing so, it di-
rected the National Institute of Environmental Health Sciences to es-
tablish an interagency to evaluate the feasibility of developing valid
alternatives to animal testing.205 This agency became known as
ICCVAM and was originally an ad hoc committee, but the ICCVAM
Authorization Act of 2000206 placed the agency on a permanent foot-
195 Id. at § 1834.9(e).
196 Id. at § 1834.9(c).
197 Cal. Sen. Jud. Comm. Rpt., 1999–2000 Sen., Reg. Sess. 2 (Apr. 25, 2000) (available
at http://info.sen.ca.gov/pub/99-00/bill/sen/sb_2051-2100/sb_2082_cfa_20000426_103549
_sen_comm.html).
198 See id. at 6 (quoting Gov. Wilson’s reason for vetoing the bill).
199 Id.
200 Id.
201 Id. at 6–7.
202 Id. at 7.
203 Cal. Sen. Jud. Comm. Rpt. 1999–2000 at 7.
204 Pub. L. No. 103-43, 107 Stat. 122 (June 10, 1993).
205 42 U.S.C. § 283e (2000).
206 Pub. L. No. 106-545, 114 Stat. 2721 (Dec. 19, 2000).
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ing.207 As mentioned in Section IX, the ICCVAM has already validated
two alternative tests, the Corrisitex and the LLNA.208
B. Chapter 476-Civil Code Section 1834.9
S.B. 2082 was given the force of law in 2000, when Chapter 476
was enacted, and it later became California Civil Code § 1834.9.209
Chapter 476 prohibits the use of animals in cosmetic testing where
alternative test methods have been scientifically validated by the
ICCVAM and subsequently adopted by the appropriate federal regula-
tory agency.210 The medical and scientific communities were critical of
the wording of S.B. 2082, which gave an exemption to medical and
pharmacological research and development, as they found it to be
“dangerously vague and overbroad.”211 The medical community felt
that the law needed further defining, lest it hamper medical and phar-
macological advancements in research and development.212
Senator O’Connell took the views of the medical and scientific in-
dustry and introduced an amended version of S.B. 2082.213 The origi-
nal version of S.B. 2082 defined the medical research exemption in the
following terms: “research related to the causes, diagnosis, treatment,
control, and prevention of physical and mental diseases and impair-
ments of humans and animals.”214 The May 3, 2000 amended version
added the following language to S.B. 2082: “or related to the develop-
ment of biomedical products, devices, or drugs as defined in Section
321(g)(1) of Title 21 of the United States Code.”215
207 42 U.S.C. § 285l-3(a) (2000); see ICCVAM & NICEATM, supra n. 151 (stating that
ICCVAM consists of forty-seven representatives from fifteen U.S. federal agencies, a list
of which is available at http://iccvam.niehs.nih.gov/about/agencies/ni_AgRepS.htm).
208 See ICCVAM & NICEATM, supra n. 151 (discussing the validation of the two al-
ternative tests).
209 Cal. Civ. Code Ann. § 1834.9.
210 Id.
211 Gillespie, supra n. 173, at 463 n. 13.
212 Id.
213 Cal. Sen. 2082, 1999–2000 Reg. Sess. (May 3, 2000) (available at http://
leginfo.ca.gov/pub/99-00/bill/sen/sb_2051-2100/sb_2082_bill_20000503_amended_sen
.pdf).
214 Cal. Sen. 2082, 1999–2000 Reg. Sess. (Feb. 25, 2000) (available at http://
leginfo.ca.gov/pub/99-00/bill/sen/sb_2051-2100/sb_2082_bill_20000225_introduced.pdf).
215 Cal. Sen. 2082, 1999–2000 Reg. Sess. (May 3, 2000). The bill was amended again
in assembly before being enacted into law. Cal. Sen. 2082, 1999–2000 Reg. Sess. (June
28, 2000) (available at http://leginfo.ca.gov/pub/99-00/bill/sen/sb_2051-2100/
sb_2082_bill_20000628_amended_asm.pdf). The assembly amendment added additional
language to the definition of medical research:
Medical research does not include the testing of an ingredient that was formerly
used in a drug, tested for the drug use with traditional animal methods to charac-
terize the ingredient and substantiate its safety for human use, and is now pro-
posed for use in a product other than a biomedical product, medical device, or
drug.
Cal. Civ. Code Ann. § 1834.9; see 21 U.S.C. §321(g)(1) (2000) (defining “drug”).
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C. Animal Welfare Groups and Standing
Another interesting amendment introduced by Chapter 476 re-
lates to the disempowerment of animal welfare groups to initiate pro-
ceedings against companies that allegedly breach the Chapter.216
Under S.B. 2082, “any entity lawfully organized under the federal In-
ternal Revenue Code as a 501(c)(3) or 501(c)(4) organization for the
purpose of protecting or providing for the welfare of animals” had locus
standi to bring an action against offending companies.217 Under pres-
sure from opposition in the medical and pharmaceutical industry, Sen-
ator O’Connell removed the right of animal welfare groups to initiate
civil proceedings “upon the belief that animal advocate groups would
instigate frivolous litigation by using Chapter 476 as a tool for indus-
try harassment.”218
VIII. EUROPEAN UNION AND CALIFORNIA
LEGISLATION COMPARED
While the scope and effectiveness of the seventh amendment to
the Cosmetics Directive has a number of limitations as discussed
above, the amendment is nevertheless a medium through which new
validated and suitable alternatives to animal testing can be developed.
Article 2 of the Cosmetics Directive expressly requires manufacturers
in the EC to safely test their products before placing them on the mar-
ket, so as not to “cause damage to human health when applied under
normal or reasonably foreseeable conditions of use . . . .”219 Article 6 of
the CDA replaced Section 7(a)(1)(d) of the 1976 Cosmetics Directive to
provide for an assessment of human health of the finished product.220
In order to achieve this, “the manufacturer shall take into considera-
tion the general toxicological profile of the ingredients, their chemical
structure and their level of exposure.”221 Article 6 also requires manu-
facturers to perform a specific assessment for children under the age of
three and for products intended exclusively for use in external inti-
mate hygiene.222
The U.S., on the other hand, does not explicitly require such an
assessment. Under the Federal Food, Drug, and Cosmetic Act of 1938,
manufacturers are under no obligation to carry out a safety assess-
ment.223 The FDA does, however, strongly advocate the use of toxico-
logical or other appropriate tests by cosmetic manufacturers to
216 Gillespie, supra n. 173, at 471.
217 Cal. Sen. 2082, 1999–2000 Reg. Sess. (Feb. 25, 2000) (as introduced, but not
enacted).
218 See Gillespie, supra n. 173, at 471 (making the point that these objections came
before the medical exemption was refined under Chapter 476).
219 Cosmetics Directive, art. 2, 1976 O.J. (L 262) at 173.
220 CDA, 2003 O.J. (L66) at 30.
221 Id.
222 Id.
223 21 U.S.C. §§ 301–397 (2000).
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substantiate the safety of their cosmetics.224 Failure to adequately
substantiate the safety of a cosmetic product may result in the product
being considered misbranded and thus subject to regulatory action, un-
less the label bears the following statement: “Warning—The safety of
this product has not been determined.”225
California Civil Code § 1834.9 applies not only to cosmetics, but
also to pesticides and other household products.226 The Cosmetics Di-
rective is more limited, as it applies specifically to cosmetic products,
even though the earlier Experimental Animals Protection Directive
was introduced to harmonize the laws in the Member States in rela-
tion to animal testing across all industries.227 Arguably, the EU felt
that little progress was being made and an impetus for reform was
needed. The Cosmetics Directive, given its specific ambit, does not
have a medical research exception. Article 1(2) of the CDA introduces
Article 4a(2.4)(a) into the Cosmetics Directive and provides for an ex-
ception in situations where “the ingredient is in wide use and cannot
be replaced by another ingredient able to perform a similar
function[.]”228
Subsection (b) further adds that “the specific human health prob-
lem is substantiated and the need to conduct animal tests is justified
and is supported by a detailed research protocol proposed as the basis
for the evaluation.”229 The Commission, after consultation with the
SCCNFP, may allow such an exception in the form of a reasoned deci-
sion.230 The French government, in the French Republic v. European
Parliament and the Council of the European Union case, perceived a
defect in this process and questioned its effectiveness in light of time
and practicality.231 It has been argued that during this time, an
unreasonable risk to human health could arise.232 The practicalities of
the exception have to be worked out.
Section 1834.9 of the California Civil Code allows for a civil pen-
alty not exceeding $5000 and injunctive relief for a violation of the pro-
vision.233 The position in the EU is somewhat different. The principle
method by which infringements of EU law are pursued is through Arti-
cle 226.234 Under Article 226, the Commission can bring a Member
State to task if they have failed to fulfill an obligation under the
Treaty.235
224 FDA, supra n. 187.
225 Id.
226 Cal. Civ. Code Ann. § 1834.9(a) (applying to manufacturers and contract testing
facilities).
227 Experimental Animals Protection Directive, 1986 O.J. (L 358) 1 (EEC).
228 CDA, 2003 O.J. (L 358) at 29.
229 Id. at 29.
230 Cosmetics Directive, art. 4a(2.4), 1976 O.J. (L 262) at 174.
231 2005 Op. Adv. Gen. Geelhoed E.C.R. I-04021 at ¶ 36.
232 Id.
233 Cal. Civ. Code Ann. § 1834.9(d).
234 EC Treaty, supra n. 11, at art. 226.
235 Id.
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The Commission can then deliver a reasoned opinion on the mat-
ter after giving the state involved the opportunity to submit its obser-
vations.236 If found to be in default of EC law, the Member State
concerned must rectify the situation without delay.237 If the Member
State does not comply with the opinion within the time period laid
down, the Commission can bring the matter before the ECJ.238 If a
Member State incorrectly transposes a directive, is late in complying,
or improperly implements the directive, the Commission has the power
under Article 226 to request immediate resolution of the situation.239
If a satisfactory result is not achieved, the matter is referred to the
ECJ.240 Article 226 is not a punitive measure, but rather seeks compli-
ance by Member States of their EC obligations. The action is taken
against the state, with “state” interpreted in the broadest sense: execu-
tive, judicial and legislative.241
A. Certifying Methods of the European Union and California
During the 1990s, the impetus to find validated alternatives to
animal testing waned in the U.S. The National Toxicology Program
Interagency Center for the Evaluation of Alternative Toxicological
Methods (NICEATM) has been in operation since 1998.242 Its Euro-
pean counterpart, the ECVAM, was set up some five years previ-
ously.243 The NICEATM has collaborated with the ICCVAM on finding
suitable validated alternatives.244
It is interesting to note there have been situations where the
ECVAM has accepted a validated alternative, and in response to this,
the ICCVAM and NICEATM have engaged in an “expedited review
process” for validation in the U.S.245 Recently, the ECVAM approved
three new validated alternatives—the EpiDerm human skin model,
the EPISKIN human skin model, and the mouse skin integrity func-
tion test [SIFT]—for in vitro skin corrosivity tests.246 These tests are
236 Id.
237 Case 69/86, Commn. v. Italian Republic, 1987 E.C.R. 780 at ¶8.
238 EC Treaty, supra n. 11, at art. 226.
239 Id.; see e.g. Joined Cases C-6/90 and C-9/90, Francovich v. Italy, 1991 E.C.R. I-
5357 (finding state liability for failure to transpose a directive); Joined Cases C-46/93
and C-48/93, 1996 E.C.R. I-01029 (discussing state liability).
240 EC Treaty, supra n. 11, at art. 226.
241 Gerrit Betlam, The King Can Do Wrong: State Liability for Breach of European
Community Law in the Post-Francovich Era, 1996 4 Web J. Current Leg. Issues, http://
webjcli.ncl.ac.uk/1996/contents4.html  (Sept. 30, 1996) (“Regardless of what organ of the
State is responsible for the unlawful act or omission, the executive, the judiciary or the
legislature, any case in which a Member State breaches Community law is in principle
covered by the liability inherent in the system of the Treaty.”).
242 Natl. Inst. Envtl. Health Sci., About NICEATM, http://iccvam.niehs.nih.gov/
about/about_NICEATM.htm (last updated Apr. 6, 2007).
243 ECVAM, supra n. 50.
244 Natl. Inst. Envtl. Health Sci., supra n. 242.
245 Gallagher, supra n. 149, at 265.
246 ICCVAM, supra n. 151.
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expected to receive regulatory acceptance in 2007–2008.247 A similar
development has taken place in the U.S., where the NICEATM and
ICCVAM have been reviewing and evaluating the EpiDerm and
EPISKIN models.248 Cooperation between EU and U.S. agencies will
hopefully result in the approval of validated alternatives in a fast and
efficient manner, while creating a uniform set of international
guidelines.
Once these validated alternatives have been approved by the
ICCVAM and NICEATM, they will then become a part of California
law.249 There is, however, an exception in the law for medical research,
which allows for the continuation of animal testing for that purpose.250
Hopefully by 2009, both the ECVAM and ICCVAM will have created a
cohesive set of validated alternatives that will reduce and, in the fu-
ture, replace the use of animals in cosmetic testing. By working to-
gether, the two agencies can expedite the process to create validated
alternatives that do not compromise consumer safety and health.
IX. FUTURE DEVELOPMENTS
The scientific community is continually developing alternative
testing methods. In the 1990s, the three Rs were developed: Replace-
ment, Reduction, and Refinement.251 Replacement involves the use of
cell cultures, reduction involves reducing the number of animals used,
and refinement is the improvement of husbandry and procedures that
will reduce or abolish the pain and suffering caused to animals.252
While all three approaches have merit, “replacement and refine-
ment are generally accepted as being more morally important than
mere reduction in the numbers of animals used.”253 The use of tissue
cultures, computer models of bodily functions, magnetic resonance
imaging, and organ cultures have been used to reduce the numbers of
animals used in research.254 While these methods apply to laboratory
testing in general, perhaps the EU could investigate their viability as
validated alternatives for cosmetic products.
247 Executive Summary, in Alternative (Non-Animal) Methods for Cosmetics Testing:
Current Status and Future Prospects, A Report Prepared in the Context of the 7th
Amendment to the Cosmetics Directive for Establishing the Timetable for Phasing Out
Animal Testing 33 Alt. Laboratory Animals 1, 9 (Chantra Eskes & Valerie Zuang eds.,
Fund for the Replacement of Animals in Med. Experiments Supp. 2005) (on file with
Animal L.).
248 ICCVAM & NICEATM, EPISKIN, and the Rat Skin Transcutaneous Electrical Re-
sistance (TER) Assay: Overview, Performance Standards and Reports, http://iccvam.
niehs.nih.gov/methods/dermal/epiderm_standard.htm (accessed Mar. 11, 2007).
249 Cal. Civ. Code Ann. § 1834.9(a) (stating that once ICCVAM has validated an alter-
native to animal testing manufacturers cannot continue testing on animals).
250 Id. at § 1834.9(e). Cal. Civ. Code Ann. § 1834.9(f)(5) defines “medical research.”
251 Richard D. Ryder, Specieism in the Laboratory, in In Defense of Animals: The Sec-
ond Wave 87, 96 (Peter Singer ed., Blackwell Publg. Ltd. 2006).
252 Id. at 96.
253 Id.
254 Id.
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It is important to note that animals can react differently than
humans to certain substances.255 For example, rats have different skin
and hair structures than humans.256 As a result, tests for skin absorp-
tion on rats “invariably over-estimate skin penetration in humans.”257
Similar criticisms have been made of skin corrosivity and irritancy
tests, as animals differ from humans in their immune, physiological,
and genetic make-up.258 Consequently, there can be variations in the
response to potentially harmful chemicals, making it difficult to pre-
dict how a human will react to the same substance.259 Rabbits are
commonly used for irritancy tests; however, the rabbit is a “notoriously
poor predictor of human skin irritation.”260
Perhaps human testing offers a more ethical alternative. Humans
are often used in clinical trials for product testing, but few are used in
cosmetic testing.261 Human volunteers have also been used in skin ir-
ritancy and sensitization tests; testers ensure their safety by using
data from earlier animal or in vitro toxicity tests.262
X. CONCLUSION AND COMMENTARY
While the judgment in France v. Parliament and Council focused
on the technicalities of partial annulment, the case has highlighted re-
cent developments in the protection of animals at the EU level.263 Pro-
ponents of animal welfare have welcomed the recent amendment to
the Cosmetics Directive.264 Hopefully by 2009, valid alternatives to
animal testing will have been found. The use of scientific developments
and human volunteers would provide a more ethical, moral, and accu-
rate alternative and result in safer cosmetic products for the con-
sumer. By 2013, there should be an almost complete prohibition on the
use of animals in cosmetic testing, irrespective of alternatives.265 The
Commission’s recognition of animal welfare is an important issue, and
its proposal to continue to examine animal welfare issues in future
proposals is a much welcomed development.
The recent developments in California provided an interesting
comparative analysis. The omission of standing for animal welfare
groups in California law means that such groups will have grave diffi-
culties filing suit.266 Chapter 476, although “a miniscule step in ending
255 Langley & Langley, supra n. 183, at § 2.
256 Id.
257 Id.
258 Id. at § 3.
259 Id.
260 Id. at § 3.
261 Langley & Langley, supra n. 183, at § 10.
262 Id.
263 Case C-244/03, Judgment, 2005 E.C.R. I-04021.
264 See e.g. Tina Nelson, First Word, 2002 AV Mag. 1 (Summer 2002) (describing
animal welfare society’s praise of the Cosmetics Directive).
265 CDA, 2003 O.J. (L 66) at 30.
266 Gillespie, supra n. 173, at 471.
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the use of animals in safety and efficacy testing . . . sets a precedent for
[the] industry.”267 With New York following suit, it may only be a mat-
ter of time before other states enact similar legislation.268
Although the recent amendments to the Cosmetics Directive will
not come into force until 2009,269 the prohibition of animal testing in
cosmetics in the EU has become an important policy objective for the
Commission, a progression that would once have seemed improbable
in the parlance of the common market. Despite criticism, the Cosmet-
ics Directive represents a tangible effort by the Council, the Commis-
sion, and the Parliament to give cognizance to animal welfare as a
discrete policy area.
267 Miller, supra n. 174, at 15.
268 See id. (stating that Assemblyman Pete Grannis (D-NY) has introduced similar
legislation in New York).
269 CDA, 2003 O.J. (L66) at 26.
